Published in Vaccine Weekly, January 8th, 2003
This center will support the company's biologics business and will be located at Shire's current site in Laval, Quebec. The project will begin immediately with completion planned for midyear 2004.
Richard de Souza, Shire director of international, said: "This investment decision serves three purposes. It recognizes the significant progress made by our biologics research team in bringing forward candidate projects for clinical development and it reinforces our commitment towards...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.